Crossmark

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214

Crossref DOI link: https://doi.org/10.1007/s00403-016-1698-8

Published Online: 2016-10-20

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Benoit, Bernice M.

Jariwala, Neha

O’Connor, Geraldine

Oetjen, Landon K.

Whelan, Timothy M.

Werth, Adrienne

Troxel, Andrea B.

Sicard, Hélène

Zhu, Lisa

Miller, Christopher

Takeshita, Junko

McVicar, Daniel W.

Kim, Brian S.

Rook, Alain H.

Wysocka, Maria http://orcid.org/0000-0002-3648-8429
Funding

Funding for this research was provided by:

National Cancer Institute (R21CA178424, Intramural Research Program)

Leukemia and Lymphoma Society (Translational research Grant)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23-AR68433, K08-AR065577-03)

American Skin Association (Research Grant)
License Information

Text and Data Mining valid from 2016-10-20

Version of Record valid from 2016-10-20
More Information

Article History

Received: 17 June 2016

Revised: 26 September 2016

Accepted: 12 October 2016

First Online: 20 October 2016

Compliance with ethical standards

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Dr. Helene Sicard is employed by Innate Pharma, Marseille, France. The authors state no conflict of interest.

Document is current

Any future updates will be listed below